GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » Inventory-to-Revenue

ChemoCentryx (ChemoCentryx) Inventory-to-Revenue : 0.36 (As of Jun. 2022)


View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ChemoCentryx's Average Total Inventories for the quarter that ended in Jun. 2022 was $4.19 Mil. ChemoCentryx's Revenue for the three months ended in Jun. 2022 was $11.76 Mil. ChemoCentryx's Inventory-to-Revenue for the quarter that ended in Jun. 2022 was 0.36.

ChemoCentryx's Inventory-to-Revenue for the quarter that ended in Jun. 2022 increased from Mar. 2022 (0.34) to Mar. 2022 (0.36)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. ChemoCentryx's Days Inventory for the three months ended in Jun. 2022 was 475.63.

Inventory Turnover measures how fast the company turns over its inventory within a year. ChemoCentryx's Inventory Turnover for the quarter that ended in Jun. 2022 was 0.19.


ChemoCentryx Inventory-to-Revenue Historical Data

The historical data trend for ChemoCentryx's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx Inventory-to-Revenue Chart

ChemoCentryx Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.03

ChemoCentryx Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.37 0.34 0.36

Competitive Comparison of ChemoCentryx's Inventory-to-Revenue

For the Biotechnology subindustry, ChemoCentryx's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChemoCentryx's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChemoCentryx's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where ChemoCentryx's Inventory-to-Revenue falls into.



ChemoCentryx Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ChemoCentryx's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Inventory-to-Revenue (A: Dec. 2021 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2020 ) + Total Inventories (A: Dec. 2021 )) / count ) / Revenue (A: Dec. 2021 )
=( (0 + 0.851) / 1 ) / 31.9
=0.851 / 31.9
=0.03

ChemoCentryx's Inventory-to-Revenue for the quarter that ended in Jun. 2022 is calculated as

Inventory-to-Revenue (Q: Jun. 2022 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Mar. 2022 ) + Total Inventories (Q: Jun. 2022 )) / count ) / Revenue (Q: Jun. 2022 )
=( (2.897 + 5.474) / 2 ) / 11.763
=4.1855 / 11.763
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ChemoCentryx  (NAS:CCXI) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ChemoCentryx's Days Inventory for the three months ended in Jun. 2022 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2022 )/Cost of Goods Sold (Q: Jun. 2022 )*Days in Period
=4.1855/0.803*365 / 4
=475.63

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

ChemoCentryx's Inventory Turnover for the quarter that ended in Jun. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2022 ) / Average Total Inventories (Q: Jun. 2022 )
=0.803 / 4.1855
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ChemoCentryx Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoCentryx (ChemoCentryx) Business Description

Traded in Other Exchanges
N/A
Address
835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Executives
Susan M Kanaya officer: SVP Finance, CFO & Secretary 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall director, 10 percent owner, officer: President, CEO and Director 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau officer: SVP, Finance & Acctg Officer C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt officer: EVP, Chief Operating Officer C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards director C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel officer: CBO and Treasurer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan officer: Principal Acctg Officer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh officer: SVP, Research C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027